| HOME >> BIOLOGY >> TECHNOLOGY |
WOBURN, Massachusetts, March 17 /PRNewswire/ -- Mercury Therapeutics, Inc. (MTI), a company that discovers and develops orally active protein kinase targeted drugs, announces that it has retained Marquant Partners LLC (http://www.marquantpartners.com) to advise on its strategic and partnering opportunities, with the aim of maximizing value for MTI's shareholders.
This appointment follows a significant amount of interest that MTI has attracted from both financial and pharmaceutical companies after its announcement in November 2007 that it had made significant progress in its small molecule AMPK activator development program. Marquant is a specialist life sciences corporate finance boutique focused on advising privately held, small cap and emerging companies on licensing transactions, M&A, divestments, corporate strategy and company formation. Marquant's founders and principals are:
Dr. Pamela Joy Barton has over 12 years experience working with companies in the life sciences sector across the full spectrum of transactions - M&A, divestments, corporate partnering/licensing (inward and outward), IPOs and financings. Prior to Marquant, Joy's positions included: Vice President, Business Development at Nabi Biopharmaceuticals; Vice President, Business Development at Sosei Co. Ltd; Commercial Director at Xenova Group Limited; member of the Pharmaceuticals and Medical Products practice at Accenture; and various roles in the oncology therapeutic area with Novartis/Sandoz.
Dean Brown has over 14 years experience working as a transaction
adviser to companies in the Life Sciences sector across the full spectrum
of transactions - M&A, divestments, corporate partnering/licensing (inward
and outward), and financings. Prior to Marquant, Dean spent almost 11 years
as a partner with the Ferghana Partners Group, a boutique transaction
advisory house operating in Europe and North America. During thi
'/>"/>
| SOURCE Mercury Therapeutics Inc. Copyright©2008 PR Newswire. All rights reserved |